Repligen Reports First Quarter 2013 Financial Results

Repligen Reports First Quarter 2013 Financial Results

 - Total Revenue and Bioprocessing Revenue Grow 28% Over First Quarter 2012 -
                 - Net Income Increases 91% to $2.3 million –
       - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT -

WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation
(Nasdaq:RGEN) today reported financial results for the first quarter ended
March 31, 2013. Below are financial and business highlights for the first
quarter of 2013, financial guidance for the year and access information for
today's discussion.

Financial Highlights:

  *Bioprocessing product revenue for the first quarter of 2013 was $11.9
    million, a 28% increase over the first quarter of 2012.
    
  *Total revenue for the first quarter of 2013 was $16.5 million, a 28%
    increase over the first quarter of 2012.
    
  *Net income increased to $2.3 million for the first quarter of 2013
    compared to $1.2 million for the first quarter of 2012; earnings per
    diluted share were $0.07 for the first quarter of 2013 compared to $0.04
    for the first quarter of 2012.
    
  *Cash and investments as of March 31, 2013 totaled $54.1 million compared
    to $50.0 million as of December 31, 2012.

Operating expenses for the three-month period ended March 31, 2013 were $12.9
million compared to $11.7 million for the same period in 2012, an increase of
$1.3 million or 11%. These operating expenses included an increase in cost of
product revenue due to higher product sales, partially offset by decreases in
both research and development expenses and selling, general and administrative
expenses. For the first quarter of 2013 compared to the same period in 2012,
research and development (R&D) expense decreased by $625,000, or 22%,
primarily due to lower spending on our clinical development programs as a
result of our strategic decision to focus on building our core bioprocessing
business. This is the Company's first financial reporting period for which
both the current and preceding year's periods reflect combined financial
results since the Company's acquisition of Novozymes Biopharma AB (now
Repligen Sweden AB) in December 2011.

"Strong demand for Protein A ligands and our growth factor products as well as
increased interest in our OPUS^® chromatography columns contributed to the
revenue gains during our first quarter. We view all of our bioprocessing
products as well positioned to benefit from the expected continued growth in
demand worldwide for monoclonal antibodies and other biologic drugs," said
Walter C. Herlihy, Ph.D., President and CEO of Repligen. "During the first
quarter, we also realized improvements in capacity utilization at Repligen
Sweden. Combined, these achievements advance the Company toward our goal to be
a best-in-class life sciences company focused on the development, production
and delivery of high-quality consumables used in the manufacture of biologic
drugs."

First Quarter Business Highlights:

  *We experienced increased demand from existing and new customers across
    multiple products including several Protein A ligands and our growth
    factor product LONG^®R3IGF-1 - a more biologically potent alternative to
    insulin for optimizing cell growth and productivity during the
    fermentation stage of biomanufacturing. We also benefited from increased
    interest in our larger (process-scale) OPUS^® chromatography columns which
    we launched in 2012.
    
  *We participated in key industry conferences, including IBC's
    Biopharmaceutical Development and Production Week, where we gave a
    presentation highlighting the time- and cost-savings achieved by adopting
    the OPUS^® line of pre-packed chromatography columns for biologic drug
    purification. We continued to build our market presence through selective
    advertising, conference presentations and other initiatives to support our
    sales and marketing efforts.
    
  *We announced in January a worldwide licensing agreement with Pfizer Inc.
    for our spinal muscular atrophy (SMA) program, in alignment with our
    strategic goal to outlicense our portfolio of therapeutic assets.

    *Under the terms of this agreement, Repligen is entitled to receive from
      Pfizer up to $65 million in milestones as well as royalties on future
      sales.
      
    *We completed the second cohort of an active Phase 1 trial in spinal
      muscular atrophy, positioning the SMA program to be fully transitioned
      to Pfizer pursuant to the terms of the license agreement.

  *We completed dosing in a Phase 1 trial of our product candidate RG2833, an
    HDAC inhibitor, in Friedreich's ataxia patients. The analysis of both
    pharmacology and biomarker activity in this clinical trial is currently
    ongoing.

Financial Guidance for 2013

The Company is reiterating its financial guidance for fiscal year 2013. This
guidance is based on expectations for our existing business and does not
include the impact on our revenue and expenses of potential milestone payments
from Pfizer, additional out-licensing agreements for our remaining clinical
assets, potential bioprocessing acquisitions or foreign currency exchange
rates.

  *Total revenue for the full year 2013 is expected to be $63-$65 million,
    including the receipt of royalties from Bristol-Myers Squibb on its U.S.
    sales of Orencia^® which the Company will no longer receive after December
    31, 2013.
    
  *Bioprocessing product revenue for the full year 2013 is expected to be
    $46-$48 million, reflecting product sales growth of 10%-15%.
    
  *Net income for the full year 2013 is expected to be $18-$20 million.
    
  *We expect to end the year 2013 with approximately $65 million in cash and
    investments.

Conference Call

Repligen will host a conference call and webcast today, May 2, at 9:00 a.m.
EDT, to discuss its first quarter 2013 financial results and corporate
developments. The live call can be accessed by dialing (866) 804-6922 for
domestic callers or (857) 350-1668 for international callers. Dial-in
participants must provide the passcode 92537192. Alternatively, an audio
webcast will be accessible via the Investor section of Repligen's website
www.repligen.com. Both the conference call and webcast will be archived for a
period of time following the live event. The replay dial-in numbers are (888)
286-8010 for domestic callers and (617) 801-6888 for international callers.
Replay listeners must provide the passcode 52274322.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and biopharmaceutical
companies worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to separate and purify monoclonal antibody therapeutics. We also
supply several growth factor products used to increase cell culture
productivity during the fermentation stage of drug manufacturing. In addition,
we have developed and market our OPUS^® series of pre-packed "plug-and-play"
chromatography columns, and we provide test kits to ensure final product
quality. Aside from our core bioprocessing business, we have a portfolio of
clinical-stage partnering assets, including a pancreatic imaging agent in
Phase 3 development and an orphan drug candidate in Phase 1 development.
Repligen's corporate headquarters are located in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release contains forward-looking statements, which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Investors are cautioned that statements in this press release which
are not strictly historical statements, constitute forward-looking statements,
including, without limitation, express or implied statements regarding future
financial performance and position, our strategic decision to focus on the
growth of our bioprocessing business, the future demand for our bioprocessing,
growth factor and chromatography products, plans and objectives for future
operations, our ability to successfully negotiate and consummate partnering
transactions for our clinical stage assets, specifically RG1068 and RG2833,
the clinical success of RG3039 and its further clinical development and our
receipt of any future payments under the terms of our agreement with Pfizer,
Pfizer's ability to terminate the license for convenience, plans and
objectives for product development and acquisitions, our market share and
product sales and other statements identified by words like "believe,"
"expect," "may," "will," "should," "seek," "anticipate," or "could" and
similar expressions. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation, risks
associated with: our ability to successfully grow our bioprocessing business,
including as a result of acquisition, commercialization or partnership
opportunities; our ability to successfully negotiate and consummate
development and commercialization partnerships for our portfolio of
clinical-stage assets on acceptable terms, if at all; the success of our
clinical trials, including our Phase 1b clinical trial of RG3039 in patients
with SMA; our ability to develop and commercialize products and the market
acceptance of our products; reduced demand for our products that adversely
impacts our future revenues, cash flows, results of operations and financial
condition; the success of current and future collaborative or supply
relationships, including our agreement with Pfizer; our ability to compete
with larger, better financed bioprocessing, pharmaceutical and biotechnology
companies; our ability to successfully integrate Repligen Sweden AB, including
achieving manufacturing efficiencies at Repligen Sweden AB; our compliance
with all Food and Drug Administration and EMEA regulations; new approaches to
the treatment of our targeted diseases; our ability to obtain, maintain and
protect intellectual property rights for our products; the risk of litigation
regarding our intellectual property rights; our limited sales capabilities;
our volatile stock price; and other risks detailed in Repligen's Annual Report
on Form 10-K on file with the Securities and Exchange Commission and the other
reports that Repligen periodically files with the Securities and Exchange
Commission. Actual results may differ materially from those Repligen
contemplated by these forward-looking statements. These forward looking
statements reflect management's current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date hereof except as
required by law.



REPLIGEN CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
                                                           
                                             Three months ended March 31,
                                             2013           2012
Revenue:                                                    
Product revenue                               $11,934,269  $9,342,601
Royalty and other revenue                     4,521,724     3,481,860
Total revenue                                 16,455,993    12,824,461
                                                           
Operating expenses:                                         
Cost of product revenue                       6,896,608     5,272,543
Cost of royalty and other revenue             576,857       462,088
Research and development                      2,183,404     2,808,463
Selling, general and administrative           3,308,099     3,428,536
Contingent consideration - fair value         (53,974)      --
adjustments
Gain on bargain purchase                      --           (314,244)
Total operating expenses                      12,910,994    11,657,386
                                                           
Income (loss) from operations                 3,544,999     1,167,075
Investment income                             61,519        31,424
Interest expense                              (13,531)      (22,381)
Other (expense) income                        29,081        109,261
                                                           
Income (loss) before income taxes             3,622,068     1,285,379
Income tax (benefit) provision                1,283,832     58,907
Net income (loss)                             $2,338,236   $1,226,472
                                                           
Earnings (loss) per share:                                  
Basic                                         $0.07        $0.04
Diluted                                       $0.07        $0.04
                                                           
Weighted average shares outstanding:                        
Basic                                         31,240,606    30,729,660
Diluted                                       31,855,428    31,009,833
                                                           
Comprehensive income (loss)                   $2,100,007   $2,314,297
                                                           
                                                           
Balance Sheet Data:                           March 31, 2013 December 31, 2012
Cash, cash equivalents and marketable         $54,055,228  $49,969,871
securities*
Working capital                               61,804,274    55,457,223
Total assets                                  97,314,768    97,010,163
Long-term obligations                         1,009,068     2,133,339
Accumulated deficit                           (102,812,341) (105,150,577)
Stockholders' equity                          87,411,034    84,124,596
                                                           
*does not include restricted cash                          

CONTACT: Sondra S. Newman
         Director Investor Relations
         Repligen Corporation
         (781) 419-1881
         snewman@repligen.com
 
Press spacebar to pause and continue. Press esc to stop.